A 65-year-old with type 2 diabetes has HbA1c 44 mmol/mol while continuing metformin, empagliflozin and semaglutide. What ongoing surveillance remains

Question

A 65-year-old with type 2 diabetes has HbA1c 44 mmol/mol while continuing metformin, empagliflozin and semaglutide. What ongoing surveillance remains appropriate?

Accepted Answer

Continue regular HbA1c and cardiovascular risk review plus kidney, foot and retinal complication screening at recommended intervals

Answer

Measure HbA1c alone every two years because normal glycaemia excludes microvascular disease

Answer

Stop all three medicines immediately and repeat testing only if osmotic symptoms recur

Answer

Continue retinal screening but cease kidney, foot and cardiovascular review because sustained HbA1c below 48 prevents further non-retinal complications

Answer

Stop surveillance because an HbA1c below 48 mmol/mol while medicated establishes permanent remission

T2DM Remission Monitoring — RACP Adult Medicine MCQ

A 65-year-old with type 2 diabetes has HbA1c 44 mmol/mol while continuing metformin, empagliflozin and semaglutide. What ongoing surveillance remains appropriate?